Logo

AZN

AstraZeneca PLC

AZN

AstraZeneca PLC • NASDAQ
$92.72 ▼ -0.64% (-0.60)
Market Cap $287.48 B
52w High $94.02
52w Low $61.24
Dividend Yield 1.56%
P/E 30.8
Volume 2.96M
Outstanding Shares 3.10B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $15.191B ▲ $8.746B ▲ $2.533B ▲ 16.674% ▼ $0.82 ▲ $5.142B ▲
Q2-2025 $14.457B ▲ $8.476B ▲ $2.45B ▼ 16.947% ▼ $0.79 ▼ $4.955B ▼
Q1-2025 $13.588B ▼ $7.673B ▼ $2.916B ▲ 21.46% ▲ $0.94 ▲ $5.035B ▲
Q4-2024 $14.891B ▲ $10.13B ▲ $1.5B ▲ 10.073% ▼ $0.49 ▲ $2.809B ▼
Q3-2024 $13.565B $8.378B $1.429B 10.534% $0.46 $4.102B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.182B ▲ $114.456B ▲ $68.485B ▲ $45.888B ▲
Q2-2025 $7.108B ▲ $112.422B ▲ $67.612B ▲ $44.719B ▲
Q1-2025 $5.395B ▼ $106.253B ▲ $65.122B ▲ $41.039B ▲
Q4-2024 $5.654B ▲ $104.035B ▼ $63.164B ▼ $40.786B ▲
Q3-2024 $4.93B $104.922B $64.117B $40.719B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.533B ▼ $5.134B ▲ $-2.001B ▲ $-2.073B ▼ $1.048B ▼ $4.448B ▲
Q2-2025 $3.127B ▲ $3.386B ▼ $-2.108B ▼ $518M ▲ $1.825B ▲ $1.463B ▼
Q1-2025 $2.916B ▲ $3.713B ▲ $-1.253B ▼ $-2.707B ▼ $-222M ▼ $3.284B ▲
Q4-2024 $1.666B ▼ $2.907B ▼ $-1.181B ▲ $-671M ▲ $994M ▲ $1.952B ▼
Q3-2024 $1.828B $3.383B $-1.514B $-4.131B $-2.242B $2.025B

Revenue by Products

Product Q2-2019Q2-2021Q2-2022Q2-2023
Andexxa
Andexxa
 $0 ▲$0 ▲$20.00M ▲$40.00M ▲
Bevespi
Bevespi
 $20.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
BioPharmaceuticals total Respiratory Immunology
BioPharmaceuticals total Respiratory Immunology
 $0 ▲$0 ▲$650.00M ▲$1.48Bn ▲
Breztri
Breztri
 $0 ▲$60.00M ▲$50.00M ▼$160.00M ▲
Brilinta
Brilinta
 $390.00M ▲$380.00M ▼$180.00M ▼$330.00M ▲
Bydureon
Bydureon
 $140.00M ▲$100.00M ▼$60.00M ▼$40.00M ▼
Calquence
Calquence
 $60.00M ▲$280.00M ▲$400.00M ▲$650.00M ▲
Crestor
Crestor
 $310.00M ▲$270.00M ▼$20.00M ▼$280.00M ▲
DalirespDaxas
DalirespDaxas
 $60.00M ▲$50.00M ▼$50.00M ▲$20.00M ▼
Enhertu
Enhertu
 $0 ▲$0 ▲$20.00M ▲$70.00M ▲
Farxiga
Farxiga
 $380.00M ▲$730.00M ▲$280.00M ▼$1.50Bn ▲
Fasenra
Fasenra
 $170.00M ▲$320.00M ▲$230.00M ▼$410.00M ▲
Faslodex
Faslodex
 $270.00M ▲$100.00M ▼$10.00M ▼$80.00M ▲
FluMist
FluMist
 $0 ▲$0 ▲$0 ▲$0 ▲
Imfinzi
Imfinzi
 $340.00M ▲$600.00M ▲$370.00M ▼$1.08Bn ▲
Kanuma
Kanuma
 $0 ▲$0 ▲$20.00M ▲$50.00M ▲
Koselugo
Koselugo
 $0 ▲$0 ▲$50.00M ▲$80.00M ▲
Lokelma
Lokelma
 $0 ▲$40.00M ▲$40.00M ▲$100.00M ▲
Lynparza
Lynparza
 $280.00M ▲$590.00M ▲$310.00M ▼$720.00M ▲
Nexium
Nexium
 $390.00M ▲$340.00M ▼$30.00M ▼$250.00M ▲
Oncology Others
Oncology Others
 $0 ▲$0 ▲$0 ▲$50.00M ▲
Onglyza
Onglyza
 $120.00M ▲$100.00M ▼$20.00M ▼$70.00M ▲
Other Others
Other Others
 $0 ▲$0 ▲$10.00M ▲$50.00M ▲
Pulmicort
Pulmicort
 $330.00M ▲$170.00M ▼$10.00M ▼$120.00M ▲
Respiratory Others
Respiratory Others
 $0 ▲$0 ▲$50.00M ▲$70.00M ▲
Roxadustat
Roxadustat
 $0 ▲$50.00M ▲$50.00M ▲$70.00M ▲
Saphnelo
Saphnelo
 $0 ▲$0 ▲$20.00M ▲$70.00M ▲
SelokenToprolXL
SelokenToprolXL
 $170.00M ▲$270.00M ▲$220.00M ▼$160.00M ▼
Soliris
Soliris
 $0 ▲$0 ▲$570.00M ▲$810.00M ▲
Strensiq
Strensiq
 $0 ▲$0 ▲$190.00M ▲$300.00M ▲
Symbicort
Symbicort
 $580.00M ▲$680.00M ▲$220.00M ▼$600.00M ▲
Synagis
Synagis
 $100.00M ▲$20.00M ▼$0 ▼$90.00M ▲
Tagrisso
Tagrisso
 $780.00M ▲$1.31Bn ▲$510.00M ▼$1.49Bn ▲
Total Oncology
Total Oncology
 $0 ▲$0 ▲$1.60Bn ▲$4.38Bn ▲
Total Other medicines
Total Other medicines
 $0 ▲$0 ▲$40.00M ▲$300.00M ▲
Ultomiris
Ultomiris
 $0 ▲$0 ▲$240.00M ▲$710.00M ▲
Vaxzevria
Vaxzevria
 $0 ▲$0 ▲$0 ▲$30.00M ▲
Zoladex
Zoladex
 $200.00M ▲$240.00M ▲$0 ▼$230.00M ▲
Arimidex
Arimidex
 $60.00M ▲$30.00M ▼$30.00M ▲$0 ▼
Casodex
Casodex
 $60.00M ▲$40.00M ▼$20.00M ▼$0 ▼
Iressa
Iressa
 $120.00M ▲$50.00M ▼$0 ▼$0 ▲
Atacand
Atacand
 $60.00M ▲$20.00M ▼$0 ▼$0 ▲
Byetta
Byetta
 $30.00M ▲$20.00M ▼$0 ▼$0 ▲
Cardiovascular Renal And Metabolism Products
Cardiovascular Renal And Metabolism Products
 $1.66Bn ▲$2.02Bn ▲$0 ▼$0 ▲
Covid19
Covid19
 $0 ▲$860.00M ▲$0 ▼$0 ▲
Covid19 Vaccine Astrazeneca C19vaz
Covid19 Vaccine Astrazeneca C19vaz
 $0 ▲$860.00M ▲$0 ▼$0 ▲
Losec Prilosec
Losec Prilosec
 $70.00M ▲$50.00M ▼$0 ▼$0 ▲
Oncology Products
Oncology Products
 $2.17Bn ▲$3.29Bn ▲$0 ▼$0 ▲
Other Cardiovascular Renal And Metabolism Products
Other Cardiovascular Renal And Metabolism Products
 $70.00M ▲$50.00M ▼$0 ▼$0 ▲
Other Diabetes
Other Diabetes
 $0 ▲$10.00M ▲$0 ▼$0 ▲
Other Oncology Products
Other Oncology Products
 $30.00M ▲$10.00M ▼$0 ▼$0 ▲
Other Products
Other Products
 $640.00M ▲$450.00M ▼$0 ▼$0 ▲
Other Products Others
Other Products Others
 $30.00M ▲$30.00M ▲$0 ▼$0 ▲
Other Respiratory Products
Other Respiratory Products
 $70.00M ▲$130.00M ▲$0 ▼$0 ▲
Respiratory Products
Respiratory Products
 $1.25Bn ▲$1.42Bn ▲$0 ▼$0 ▲
Seroquel Xr Ir
Seroquel Xr Ir
 $30.00M ▲$20.00M ▼$0 ▼$0 ▲
Duaklir
Duaklir
 $0 ▲$0 ▲$0 ▲$0 ▲
Movantik Moventig
Movantik Moventig
 $50.00M ▲$0 ▼$0 ▲$0 ▲
Symlin
Symlin
 $10.00M ▲$0 ▼$0 ▲$0 ▲
Tudorza Eklira
Tudorza Eklira
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement AstraZeneca’s income statement shows a company that has grown quickly and become more profitable over the last several years. Revenue has climbed steadily each year, helped by strong demand in oncology, cardiovascular, respiratory, and rare disease drugs. Profitability has improved even faster than sales: gross profit has expanded, and operating earnings have strengthened as the company scales up newer, higher‑margin medicines. There was a soft patch a few years ago when profits were squeezed by integration costs and heavy investment, but earnings have since rebounded sharply. Overall, the trend is one of a larger, more efficient, and more profitable business, though still dependent on continued success from a relatively concentrated set of blockbuster products.

Balance Sheet

Balance Sheet The balance sheet reflects a large, research‑intensive pharmaceutical group with meaningful use of debt but a stronger equity base than in the past. Total assets have grown significantly, largely driven by acquisitions and an expanding portfolio of marketed drugs and pipeline assets. Debt rose when the company bought Alexion and has stayed at a sizable level, but shareholder equity has also increased, which helps support the capital structure. Cash on hand is healthy but not excessive, suggesting reliance on ongoing cash generation rather than large idle balances. In simple terms, AstraZeneca looks solid but not ultra‑conservative: it has a bigger, more robust asset base and equity cushion than a few years ago, balanced by a noticeable but manageable debt load.

Cash Flow

Cash Flow Cash generation has become a clear strength. Operating cash flow has increased consistently, showing that earnings are backed by real cash, not just accounting gains. Free cash flow is solidly positive and has grown over time even as the company has stepped up its investment in new facilities, manufacturing capacity, and technology. Capital spending has risen, reflecting long‑term commitment to research, biologics, and complex manufacturing, but it remains well covered by cash from operations. The picture is of a business that can both fund its own growth and service its obligations from internal cash, which is important in an industry where new drug development is expensive and risky.

Competitive Edge

Competitive Edge AstraZeneca holds a strong competitive position among global biopharma companies. It is deeply entrenched in several high‑value therapeutic areas—especially cancer, cardiovascular and kidney disease, respiratory conditions, and rare diseases—giving it multiple, diversified revenue pillars. Flagship drugs in oncology, heart and kidney disease, and rare disorders help anchor its market presence and brand recognition with physicians. The Alexion acquisition added a leading rare disease franchise with limited competition and high switching costs. Extensive partnerships and a broad global commercial network support the launch and uptake of new products. The main competitive pressures come from other big pharma and biotech players targeting similar diseases, future generic and biosimilar competition as patents expire, and ongoing pricing and reimbursement pressure from health systems and regulators.

Innovation and R&D

Innovation and R&D Innovation is one of AstraZeneca’s main defining traits. The company is heavily invested in advanced drug technologies such as antibody‑drug conjugates for cancer, cutting‑edge biologics, and next‑generation modalities in cell and gene therapy. It applies genomics, data science, and artificial intelligence across research and clinical trials to improve target selection and trial design. The pipeline is broad and deep, with many late‑stage oncology and rare‑disease programs and an ambitious plan to launch a large number of new medicines over the rest of the decade. Acquisitions and collaborations—like those with Daiichi Sankyo, Merck, and newer deals in cell and gene therapy—further expand its scientific reach. The flip side is high R&D spend and the usual clinical risks: setbacks, delays, or safety issues in key programs could affect the growth narrative.

Summary

Overall, AstraZeneca looks like a mature but still fast‑evolving biopharma leader. Financially, it has transitioned from a heavy investment and integration phase into a period of stronger growth and improving profitability, backed by solid cash generation. Its balance sheet shows a meaningful but seemingly manageable level of debt, supported by a growing equity base and a diversified portfolio of marketed drugs. Competitively, the company is well positioned in some of the most attractive areas of medicine, with a particularly strong stance in oncology and rare diseases. Its innovation engine appears robust, with advanced technologies and a very active pipeline aimed at delivering substantial additional growth. The main uncertainties center on execution: sustaining innovation, navigating patent expiries and pricing pressure, integrating acquisitions, and delivering on long‑term revenue targets in a highly competitive and regulated industry.

NEWS

November 23, 2025 · 7:01 PM UTC

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Read more

November 21, 2025 · 2:05 PM UTC

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Read more

November 9, 2025 · 4:33 PM UTC

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Read more

November 7, 2025 · 9:00 AM UTC

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Read more

November 6, 2025 · 7:00 AM UTC

AstraZeneca's 9M and Q3 2025 Financial Results

Read more